FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891610296> ?p ?o ?g. }

• W2891610296 endingPage "33733" @default.
• W2891610296 startingPage "33719" @default.
• W2891610296 abstract "In current clinical practices, up to 27% of all breast cancer patients receive neoadjuvant chemotherapy. High pathological complete response rate is frequently associated with tumor-infiltrating lymphocytes. Additionally, circulating immune cells are also often linked to chemotherapy response. We performed a retrospective analysis on a cohort of 112 breast cancer patients (79 triple-negative, 33 hormone receptor-negative/HER2-positive) treated with standard neoadjuvant chemotherapy. Eosinophil and lymphocyte counts were collected from whole blood at baseline and during follow-ups and their associations with pathological complete response, relapse, disease-free and breast cancer-specific survival were analyzed. We observed a higher pathological complete response rate in patients who presented at baseline a relative eosinophil count ≥ 1.5% (55.6%) than in those with a relative eosinophil count < 1.5% (36.2%)(p = 0.04). An improvement in breast cancer-specific survival in patients with high relative eosinophil count (p = 0.05; HR = 0.336; 95% CI = 0.107-1.058) or with high relative lymphocyte count (threshold = 17.5%, p = 0.01; HR = 0.217; 95% CI = 0.060-0.783) were also observed. Upon combining the two parameters into the eosinophil x lymphocyte product with a threshold at 35.8, associations with pathological complete response (p = 0.002), relapse (p = 0.028), disease-free survival (p = 0.012) and breast cancer-specific survival (p = 0.001) were also recorded. In conclusion, the relative eosinophil count and eosinophil x lymphocyte product could be promising, affordable and accessible new biomarkers that are predictive for neoadjuvant chemotherapy response and prognostic for longer survival in triple-negative and hormone receptors-negative/HER2-positive breast cancers. Confirmation of these results in a larger patient population is needed." @default.
• W2891610296 created "2018-09-27" @default.
• W2891610296 creator A5002598380 @default.
• W2891610296 creator A5027538973 @default.
• W2891610296 creator A5051342394 @default.
• W2891610296 creator A5056716594 @default.
• W2891610296 creator A5071675004 @default.
• W2891610296 creator A5083510035 @default.
• W2891610296 creator A5084086966 @default.
• W2891610296 date "2018-09-14" @default.
• W2891610296 modified "2023-10-14" @default.
• W2891610296 title "Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment" @default.
• W2891610296 cites W1476833121 @default.
• W2891610296 cites W1559606728 @default.
• W2891610296 cites W1586470106 @default.
• W2891610296 cites W1757407923 @default.
• W2891610296 cites W1966656255 @default.
• W2891610296 cites W1975401903 @default.
• W2891610296 cites W1979379635 @default.
• W2891610296 cites W1982453726 @default.
• W2891610296 cites W1990075382 @default.
• W2891610296 cites W1996249995 @default.
• W2891610296 cites W1998667229 @default.
• W2891610296 cites W2036123202 @default.
• W2891610296 cites W2037801848 @default.
• W2891610296 cites W2043017894 @default.
• W2891610296 cites W2043183348 @default.
• W2891610296 cites W2048059530 @default.
• W2891610296 cites W2048970545 @default.
• W2891610296 cites W2074357581 @default.
• W2891610296 cites W2075894019 @default.
• W2891610296 cites W2088574179 @default.
• W2891610296 cites W2107863654 @default.
• W2891610296 cites W2112128548 @default.
• W2891610296 cites W2118605519 @default.
• W2891610296 cites W2133650808 @default.
• W2891610296 cites W2147415463 @default.
• W2891610296 cites W2157058802 @default.
• W2891610296 cites W2157285286 @default.
• W2891610296 cites W2158036908 @default.
• W2891610296 cites W2164540420 @default.
• W2891610296 cites W2169914436 @default.
• W2891610296 cites W2171778498 @default.
• W2891610296 cites W2173906549 @default.
• W2891610296 cites W2346108121 @default.
• W2891610296 cites W2397854274 @default.
• W2891610296 cites W2581911737 @default.
• W2891610296 cites W2724894887 @default.
• W2891610296 cites W2740169839 @default.
• W2891610296 cites W2762055451 @default.
• W2891610296 cites W2784062576 @default.
• W2891610296 cites W2791153774 @default.
• W2891610296 cites W2803304299 @default.
• W2891610296 doi "https://doi.org/10.18632/oncotarget.26120" @default.
• W2891610296 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6154746" @default.
• W2891610296 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30263098" @default.
• W2891610296 hasPublicationYear "2018" @default.
• W2891610296 type Work @default.
• W2891610296 sameAs 2891610296 @default.
• W2891610296 citedByCount "18" @default.
• W2891610296 countsByYear W28916102962020 @default.
• W2891610296 countsByYear W28916102962021 @default.
• W2891610296 countsByYear W28916102962022 @default.
• W2891610296 countsByYear W28916102962023 @default.
• W2891610296 crossrefType "journal-article" @default.
• W2891610296 hasAuthorship W2891610296A5002598380 @default.
• W2891610296 hasAuthorship W2891610296A5027538973 @default.
• W2891610296 hasAuthorship W2891610296A5051342394 @default.
• W2891610296 hasAuthorship W2891610296A5056716594 @default.
• W2891610296 hasAuthorship W2891610296A5071675004 @default.
• W2891610296 hasAuthorship W2891610296A5083510035 @default.
• W2891610296 hasAuthorship W2891610296A5084086966 @default.
• W2891610296 hasBestOaLocation W28916102961 @default.
• W2891610296 hasConcept C121608353 @default.
• W2891610296 hasConcept C126322002 @default.
• W2891610296 hasConcept C143998085 @default.
• W2891610296 hasConcept C203014093 @default.
• W2891610296 hasConcept C2776042228 @default.
• W2891610296 hasConcept C2776694085 @default.
• W2891610296 hasConcept C2777037409 @default.
• W2891610296 hasConcept C2780110267 @default.
• W2891610296 hasConcept C530470458 @default.
• W2891610296 hasConcept C71924100 @default.
• W2891610296 hasConcept C90924648 @default.
• W2891610296 hasConceptScore W2891610296C121608353 @default.
• W2891610296 hasConceptScore W2891610296C126322002 @default.
• W2891610296 hasConceptScore W2891610296C143998085 @default.
• W2891610296 hasConceptScore W2891610296C203014093 @default.
• W2891610296 hasConceptScore W2891610296C2776042228 @default.
• W2891610296 hasConceptScore W2891610296C2776694085 @default.
• W2891610296 hasConceptScore W2891610296C2777037409 @default.
• W2891610296 hasConceptScore W2891610296C2780110267 @default.
• W2891610296 hasConceptScore W2891610296C530470458 @default.
• W2891610296 hasConceptScore W2891610296C71924100 @default.
• W2891610296 hasConceptScore W2891610296C90924648 @default.
• W2891610296 hasIssue "72" @default.
• W2891610296 hasLocation W28916102961 @default.
• W2891610296 hasLocation W28916102962 @default.

• next